Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Topoisomerase II Alpha (TOPO2A) as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

NCT04055753 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT04055753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04055753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Topoisomerase II Alpha (TOPO2A) as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Lead sponsor
Fox Chase Cancer Center
Phase
Observational
Overall status
Active, not recruiting
Start date
August 12, 2016
Completion date
October 31, 2027
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma